Analysis of the effect of the active compound of green tea (EGCG) on the proliferation of peripheral blood mononuclear cells

BMC Complementary and Alternative Medicine

Noha Al-Saleh¹  Medhat Oteifa¹  Sami Asfar⁴  Raj Raghupathy²  Farid Saleh³ 

[1] Department of Surgery, Kuwait Cancer Control Centre, Kuwait City, Kuwait;Department of Microbiology, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait;Department of Anatomy, College of Medicine, Al-Imam Mohammad Ibn Saud Islamic University, Riyadh, Kingdom of Saudi Arabia;Department of Surgery, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait

关键词: Green tea;    IFN-γ;    PBMC;    EGCG;   

Others  :  1086835
DOI  :  10.1186/1472-6882-14-322

 received in 2013-09-09, accepted in 2014-08-27,  发布年份 2014

【 摘 要 】

Background

Cancer immunotherapy requires proper manipulation of the immune system, lymphocytes in particular, in order to identify and destroy the cancer cells as non-self. In this study we investigated the effect of the flavonoid present in green tea, namely epigallocatechin-3-gallate (EGCG), on the proliferation of, and IFN-γ production by, peripheral blood mononuclear cells (PBMC) from breast cancer patients stimulated with a mitogen, anti-CD3 and the common breast cancer peptides Her-2/neu, and p53.

Methods

Blood samples were collected from 25 patients with breast cancer at the Kuwait Cancer Control Centre (KCCC). The patients were newly diagnosed, and had not undergone any treatment or surgery at the time of sample collection. The control group consisted of 25 healthy women age-matched (±5 years) to the patients. PBMC were isolated from the patients and controls, and were cultured separately with the mitogen PHA, anti-CD3 antibodies, and Her-2/neu and p53 in the presence or absence of standardized doses of EGCG. The degree of proliferation and interferon-γ [IFN-γ) release were then analyzed.

Results

EGCG significantly suppressed the proliferation of PBMC in response to stimulation separately with (i) the mitogen, (ii) anti-CD3, and (iii) the cancer antigen peptides. IFN-γ production was also significantly suppressed by EGCG in vitro.

Conclusions

EGCG appears to have an immunosuppressive effect on the proliferation of PBMC, indicating that EGCG is worth exploring for immunomodulatory effects in autoimmune diseases and tissue transplantation.

【 授权许可】

   
2014 Saleh et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Beltz LA, Bayer DK, Moss AL, Simet IM: Mechanisms of cancer prevention by green and black tea polyphenols. Anticancer Agents Med Chem 2006, 6:389-406.
• [2]Khan N, Afaq F, Saleem M, Ahmad N, Mukhtar H: Targeting multiple signaling pathways by green tea polyphenol (--)-epigallocatechin-3-gallate. Cancer Res 2006, 66:2500-2505.
• [3]Higdon JV, Frei B: Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr 2003, 43:89-143.
• [4]Zaveri NT: Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications. Life Sci 2006, 78:2073-2080.
• [5]Mukhtar H, Ahmad N: Tea polyphenols: prevention of cancer and optimizing health. Am J Clin Nutr 2000, 71:1698-704S.
• [6]Palermo C, Martin Hernando J, Dertinger S, Kende A, Gasiewicz T: Identification of potential aryl hydrocarbon receptor antagonists in green tea. Chem Res Toxicol 2003, 16:865-872.
• [7]Yang CS, Maliakal P, Meng X: Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol 2002, 42:25-54.
• [8]Chen D, Daniel KG, Kuhn DJ, Kazi A, Bhuiyan M, Li L, Wang Z, Wan SB, Lam WH, Chan TH, Dou QP: Green tea and tea polyphenols in cancer prevention. Front Biosci 2004, 9:2618-2631.
• [9]Chow HH, Cai Y, Hakim IA, Crowell JA, Shahi F, Brooks CA, Dorr RT, Hara Y, Alberts DS: Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 2003, 9:3312-3319.
• [10]Chow HH, Hakim IA, Vining DR, Crowell JA, Ranger-Moore J, Chew WM, Celaya CA, Rodney SR, Hara Y, Alberts DS: Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of polyphenon E in healthy individuals. Clin Cancer Res 2005, 11:4627-4633.
• [11]Ahn WS, Yoo J, Huh SW, Kim CK, Lee JM, Namkoong SE, Bae SM, Lee IP: Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. Eur J Cancer Prev 2003, 12:383-390.
• [12]Saleh F, Crotty K, Hersey P, Menzies S: Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen melan-A/MART-1. Int J Cancer 2001, 94:551-557.
• [13]Palmieri B, Saleh F, Benuzzi G, Mousa A, Shamseddine A, Al-Sebeih K: Polydimethylsiloxane: an effective immune adjuvant and slow-release cytokine medium for local cancer treatment. J Carcinogenesis 2008, 7:1-7.
• [14]Wada Y, Nakashima O, Kutami R, Yamamoto O, Kojiro M: Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology 1998, 27:407-414.
• [15]Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003, 348:203-213.
• [16]Dhodapkar MV, Krasovsky J, Osman K, Geller MD: Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med 2003, 198:1753-1757.
• [17]Suzuki H, Graziano DF, McKolanis J, Finn OJ: T Cell-Dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin Cancer Res 2005, 11:1521-1526.
• [18]Garbe AI, Vermeer B, Gamrekelashvili J, Wasielewski R, Greten FR, Westendorf AM, Buer J, Schmid RM, Manns MP, Korangy F, Greten TF: Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses. Cancer Res 2006, 66:508-516.
• [19]Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U: Natural T cell immunity against cancer. Clin Cancer Res 2003, 9:4296-4303.
• [20]Korangy F, Ormandy LA, Bleck JS, Klempnauer J, Wilkens L, Manns MP, Greten TF: Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res 2004, 10:4332-4341.
• [21]Stern P, Beverley P, Carroll M: Cancer Vaccines and Immunotherapy. Cambridge, UK: Cambridge University Press; 2000.
• [22]Kang H, Lee J, Song C, Han H, Shin B, Pai S, Hung C, Trimble C, Lim J, Kim T, Wu T: Epigallocatechin-3-gallate enhances CD8+ T cell–mediated antitumor immunity induced by DNA vaccination. Cancer Res 2007, 67:802-811.
• [23]Kawai K, Tsuno NH, Kitayama J, Okaji Y, Yazawa K, Asakage M, Hori N, Watanabe T, Takahashi K, Nagawa H: Epigallocatechin gallate attenuates adhesion and migration of CD8+ T cells by binding to CD11b. J Allergy Clin Immunol 2004, 113:1211-1217.
• [24]Springer TA: Adhesion receptors of the immune system. Nature 1990, 346:425-434.
• [25]Nielsen HV, Christensen JP, Andersson EC, Marker O, Thomsen AR: Expression of type 3 complement receptor on activated CD8+ T cells facilitates homing to inflammatory sites. J Immunol 1994, 153:2021-2028.
• [26]Wagner C, Hansch GM, Stegmaier S, Denefleh B, Hug F, Schoels M: The complement receptor 3, CR3 (CD11b/CD18), on T lymphocytes: activation-dependent up-regulation and regulatory function. Eur J Immunol 2001, 31:1173-1180.
• [27]Fiorentini S, Licenziati S, Alessandri G, Castelli F, Caligaris S, Bonafede M: CD11b expression identifies CD8+CD28+ T lymphocytes with phenotype and function of both naive/memory and effector cells. J Immunol 2001, 166:900-907.
• [28]Wang M, Guo C, Li M: A case–control study on the dietary risk factors of upper digestive tract cancer. Zhonghua Liu Xing Bing Xue Za Zhi 1999, 20:95-97.
• [29]Sasazuki S, Inoue M, Miura T, Iwasaki M, Tsugane S: Plasma tea polyphenols and gastric cancer risk: a case–control study nested in a large population-based prospective study in Japan. Cancer Epidemiol Biomarkers Prev 2008, 17:343-351.
• [30]Dai Q, Shu XO, Li H, Yang G, Shrubsole MJ, Cai H, Ji B, Wen W, Franke A, Gao YT, Zheng W: Is green tea drinking associated with a later onset of breast cancer? Ann Epidemiol 2010, 20:74-81.
• [31]Larsson SC, Wolk A: Tea consumption and ovarian cancer risk in a population-based cohort. Arch Intern Med 2005, 165:2683-2686.
• [32]Zhang M, Lee AH, Binns CW, Xie X: Green tea consumption enhances survival of epithelial ovarian cancer. Int J Cancer 2004, 112:465-469.
• [33]Kurahashi N, Sasazuki S, Iwasaki M, Inoue M, Tsugane S: Green tea consumption and prostate cancer risk in Japanese men: a prospective study. Am J Epidemiol 2008, 167:71-77.
• [34]Shanafelt TD, Call TG, Zent CS, LaPlant B, Bowen DA, Roos M, Secreto CR, Ghosh AK, Kabat BF, Lee MJ, Yang CS, Jelinek DF, Erlichman C, Kay NE: Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol 2009, 27:3808-3814.
• [35]Wu D, Guo Z, Ren Z, Guo W, Meydani SN: Green tea EGCG suppresses T cell proliferation through impairment of IL-2/IL-2 receptor signaling. Free Radic Biol Med 2009, 47:636-643.
• [36]Aktas O, Prozorovski T, Smorodchenko A, Savaskan N, Lauster R, Kloetzel PM, Infante-Duarte C, Brocke S, Zipp F: Green tea epigallocatechin-3-gallate mediates T cellular NF-kB inhibition and exerts neuroprotection in Autoimmune Encephalomyelitis. J Immunol 2004, 173:5794-5800.
• [37]Hu ZQ, Toda M, Okubo S, Hara Y, Shimamura T: Mitogenic activity of (-)epigallocatechin gallate on B-cells and investigation of its structure function relationship. Int J Immunopharmacol 1992, 14:1399-1407.
• [38]Wilasrusmee C, Kittur S, Siddiqui J, Bruch D, Wilasrusmee S, Kittur DS: In vitro immunomodulatory effects of ten commonly used herbs on murine lymphocytes. J Altern Complement Med 2002, 8:467-475.
• [39]Zvetkova E, Wirleitner B, Tram NT, Schennach H, Fuchs D: Aqueous extracts of Crinum latifolium (L.) and Camellia sinensis show immunomodulatory properties in human peripheral blood mononuclear cells. Int Immunopharmacol 2001, 1:2143-2150.
• [40]Ahn SC, Kim GY, Kim JH, Baik SW, Han MK, Lee HJ, Moon DO, Lee CM, Kang JH, Kim BH, Oh YH, Park YM: Epigallocatechin-3-gallate, constituent of green tea, suppresses the LPS-induced phenotypic and functional maturation of murine dendritic cells through inhibition of mitogen-activated protein kinases and NF-kappaB. Biochem Biophys Res Commun 2004, 313:148-155.
• [41]Yoneyama S, Kawai K, Tsuno NH, Okaji Y, Asakage M, Tsuchiya T, Yamada J, Sunami E, Osada T, Kitayama J, Takahashi K, Nagawa H: Epigallocatechin gallate affects human dendritic cell differentiation and maturation. J Allergy Clin Immunol 2008, 121:209-214.
• [42]Pae M, Ren Z, Meydani M, Shang F, Meydani SN, Wu D: Epigallocatechin-3-Gallate directly suppresses T cell proliferation through impaired IL-2 utilization and cell cycle progression. J Nutr 2010, 140:1509-1515.
• [43]Mukherjee S, Siddiqui MA, Dayal S, Ayoub YZ, Malathi K: Epigallocatechin-3-gallate suppresses proinflammatory cytokines and chemokines induced by Toll-like receptor 9 agonists in prostate cancer cells. J Inflamm Res 2014, 17:89-101.
• [44]Ren X, Guo X, Chen L, Guo M, Peng N, Li R: Attenuated migration by green tea extract (-)-epigallocatechin gallate (EGCG): involvement of 67 kDa laminin.receptor internalization in macrophagic cells. Food Funct 2014, 5:1915-1919.
• [45]Chen SS, Michael A, Butler-Manuel SA: Advances in the treatment of ovarian cancer: a potential role of antiinflammatory phytochemicals. Discov Med 2012, 13:7-17.
• [46]Ellis LZ, Liu W, Luo Y, Okamoto M, Qu D, Dunn JH, Fujita M: Green tea polyphenol epigallocatechin-3-gallate suppresses melanoma growth by inhibiting inflammasome and IL-1β secretion. Biochem Biophys Res Commun 2011, 414:551-556.
• [47]Singh T, Katiyar SK: Green tea catechins reduce invasive potential of human melanoma cells by targeting COX-2, PGE2 receptors and epithelial-to-mesenchymal transition. PLoS One 2011, 6:e25224.
• [48]Hoffmann J, Junker H, Schmieder A, Venz S, Brandt R, Multhoff G, Falk W, Radons J: EGCG downregulates IL-1RI expression and suppresses IL-1-induced tumorigenic factors in human pancreatic adenocarcinoma cells. Biochem Pharmacol 2011, 82:1153-1162.
• [49]Kürbitz C, Heise D, Redmer T, Goumas F, Arlt A, Lemke J, Rimbach G, Kalthoff H, Trauzold A: Epicatechin gallate and catechin gallate are superior to epigallocatechin gallate in growth suppression and anti-inflammatory activities in pancreatic tumor cells. Cancer Sci 2011, 102:728-734.